CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review

The cyclin D-CDK4/6 complexes play a pivotal role in controlling the cell cycle. Deregulation in cyclin D-CDK4/6 pathway has been described in many types of cancer and it invariably leads to uncontrolled cell proliferation. Many efforts have been made to develop a target therapy able to inhibit CDK4...

Full description

Bibliographic Details
Main Authors:	Gian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, Alessandra Dall’Acqua, Andrea Vecchione, Gustavo Baldassarre, Barbara Belletti
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-05-01
Series:	Frontiers in Oncology
Subjects:	CDK4/6 inhibitors drug resistance small inhibitors chemotherapy combination therapy endocrine therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.891580/full

Similar Items

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models
by: Hu W, et al.
Published: (2023-12-01)

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]
by: Wardoyo S, et al.
Published: (2023-12-01)

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
by: Elisa Agostinetto, et al.
Published: (2023-11-01)

CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
by: Fiona H. Zhou, et al.
Published: (2023-03-01)

Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis
by: Zhihao Zhang, et al.
Published: (2024-09-01)

First-line endocrine therapy combined with CDK 4/6 inhibitor in disseminated carcinomatosis of bone marrow (DCBM) luminal breast cancer: a case report
by: Eko Adhi Pangarsa, et al.
Published: (2024-12-01)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
by: Ioana-Miruna Stanciu, et al.
Published: (2023-03-01)

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
by: Sibylle Loibl, et al.
Published: (2022-03-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature
by: Giada Targato, et al.
Published: (2022-12-01)

HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study
by: Yingbo Shao, et al.
Published: (2022-08-01)

Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-08-01)

Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2– advanced breast cancer
by: Qi Zhao, et al.
Published: (2024-10-01)

Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer
by: Jinmei Zhou, et al.
Published: (2022-12-01)

Insights into the structural and functional activities of forgotten Kinases: PCTAIREs CDKs
by: Javad Karimbayli, et al.
Published: (2024-06-01)

CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis
by: Cailu Luo, et al.
Published: (2024-08-01)

Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.
by: Marta Kovatcheva, et al.
Published: (2018-01-01)

Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study
by: Yun Wu, et al.
Published: (2024-04-01)

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
by: Jhin Jieh Lim, et al.
Published: (2022-08-01)

Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis
by: Fei Tong, et al.
Published: (2024-06-01)

Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective
by: Marek Ziobro, et al.
Published: (2023-02-01)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
by: Jiao Yang, et al.
Published: (2023-01-01)

Ribociclib in patient with hormone-positive HER2-negative breast cancer with brain metastases: a case report
by: N. S. Prizova, et al.
Published: (2022-06-01)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
by: Alessandra Dall'Acqua, et al.
Published: (2017-08-01)

Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
by: Monika Lukoseviciute, et al.
Published: (2021-09-01)

Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations
by: E. N. Imyanitov
Published: (2016-09-01)

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
by: Lanshu Xiao, et al.
Published: (2023-12-01)

CDK7 in breast cancer: mechanisms of action and therapeutic potential
by: Ying Gong, et al.
Published: (2024-04-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
by: ZHANG Baihong, et al.
Published: (2019-01-01)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
by: Ran Sun, et al.
Published: (2022-04-01)

Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
by: Al-Batsh T, et al.
Published: (2025-03-01)

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials
by: Dongqing Pu, et al.
Published: (2024-01-01)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
by: Viola Cogliati, et al.
Published: (2022-03-01)

Safety of Abemaciclib in Indian Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced and/or Metastatic Breast Cancer: A Multicenter, Nonrandomized, Open-Label, Single-Arm, Phase 4 Study
by: Dinesh Chandra Doval, et al.

Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review
by: Maissoune Hajir, et al.
Published: (2023-09-01)

CDK4/6 and aromatase inhibitors as first‐line treatment in metastatic high‐grade neuroendocrine carcinoma of the breast: A case report
by: Dionysia N. Zouki, et al.
Published: (2024-07-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay
by: Jing Li, et al.
Published: (2019-10-01)

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
by: Francesca Citron, et al.
Published: (2021-06-01)